|
|
||||||||
Investigative Ophthalmology & Visual Science, Vol 36, 1885-1892, Copyright © 1995 by Association for Research in Vision and Ophthalmology
ARTICLES AND REPORTS |
JR Berlie, LJ Iversen, HS Blaxall, ME Cooley, DM Chacko and DB Bylund
Department of Ophthalmology, University of Nebraska Medical Center, Omaha 68198-6260, USA.
PURPOSE. To identify and characterize the alpha-2 adrenergic receptor subtypes present in the bovine neurosensory retina. METHODS. Radioligand saturation and inhibition binding assays were performed with the antagonist radioligands [3H]RX821002 and [3H]rauwolscine. RESULTS. [3H]RX821002 bound to a single class of receptors with the characteristics of an alpha-2 adrenergic receptor with an affinity (KD) of 0.16 nM and a receptor density (Bmax) of 1500 fmol/mg protein. Correlation of the affinities (pKi values) for nine antagonists in the bovine neurosensory retina with the alpha-2D receptor of the bovine pineal gave a correlation coefficient of 0.99. The correlation coefficients for the alpha-2A (0.84), alpha-2B (0.36), and alpha-2C (0.39) subtypes were much lower. The presence of a minor population of alpha-2B or alpha-2C receptors was excluded. CONCLUSIONS. A high density of alpha-2D adrenergic receptors is present in the bovine neurosensory retina. Neither the alpha-2B nor the alpha-2C subtype is detectable.
This article has been cited by other articles:
![]() |
F B Kalapesi, M T Coroneo, and M A Hill Human ganglion cells express the alpha-2 adrenergic receptor: relevance to neuroprotection Br. J. Ophthalmol., June 1, 2005; 89(6): 758 - 763. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Wikberg-Matsson and U. Simonsen Potent {alpha}2A-Adrenoceptor-Mediated Vasoconstriction by Brimonidine in Porcine Ciliary Arteries Invest. Ophthalmol. Vis. Sci., August 1, 2001; 42(9): 2049 - 2055. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. B. Bylund and D. M. Chacko Characterization of {alpha}2 Adrenergic Receptor Subtypes in Human Ocular Tissue Homogenates Invest. Ophthalmol. Vis. Sci., September 1, 1999; 40(10): 2299 - 2306. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. B. Bylund, L. J. Iversen, W. J. Matulka, and D. M. Chacko J. Pharmacol. Exp. Ther., June 1, 1997; 281(3): 1171 - 1177. [Abstract] [Full Text] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |